Eli Lilly
-
Neurology startup Magnolia Neurosciences raises $31M in Series A round
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer’s disease.
-
Trump attacks Pfizer, drug industry over price increases
The administration also quietly pulled out of its widely publicized pay-for-performance program for Novartis’ CAR-T Kymriah.
-
A new way to access scientific papers?
For researchers who aren’t affiliated with an academic library, finding scientific papers can be time-consuming and expensive—and organizing and sharing them with co-workers can be even harder. A new tool by DeepDyve looks to help researchers address this gap.
-
Senate confirms Alex Azar as HHS Secretary
In a 55-43 vote, the Senate has confirmed Alex Azar as the new secretary of the Department of Health and Human Services. President Donald Trump nominated Azar in November following the resignation of Tom Price.
-
Patents will expire on these medications in 2018
Pinpointing the expiration date of drug patents can make filing taxes look like child’s play. Each drug has wide ranging intellectual property, with timelines that are ever-changing. That said, here’s a list of 26 drugs that will probably go off patent in 2018.
-
HHS nominee Alex Azar talks drug pricing and ACA politics
As HHS secretary, Alex Azar would oversee a trillion-dollar budget, over 90,000 employees, and a healthcare system that is ground-zero for heated bipartisan politics. So where does Trump’s new nominee stand on the major issues?
-
Former Eli Lilly USA president in line to be next HHS Secretary (Updated)
Alex Azar also has some particularly relevant experience as deputy Health and Human Services Secretary under George W. Bush, but will his pharma background put off a president who has been critical of the drug industry’s pricing practices?
-
States investigate pharma companies, CVS Health as diabetes drug prices reach record highs
The United States is one of the few developed countries without regulations on prescription drug pricing.
-
More options for psoriasis, as Big Pharma jostles for market share
Coming soon to a screen near you: more psoriasis ads. FDA has approved J&J’s guselkumab (Tremfya) for use in moderate to severe plaque psoriasis. Despite plenty of competition, annual sales are expected to be north of $1 billion by 2022.
-
Eli Lilly’s CEO on the good, the bad… and the beautiful?
In an interview with MedCity News on day three of the BIO International Convention, Ricks discussed his company’s newly expanded R&D facility in San Diego, the challenges of drug discovery, and the ultimate reward.
-
Improving the patient experience without undermining care navigation
Since the start of the pandemic, patients have more options as to how they access healthcare than ever before. A new report from Bright.MD shares insights on how to create a hybrid model of care that raises awareness of those choices and their benefits.
-
Not sold: FDA demands more data on Eli Lilly’s rheumatoid arthritis drug
Keep the champagne on ice. In an unexpected twist, the FDA has requested more dosage and safety data for Eli Lilly’s baricitinib (Olumiant) — a delay that could cost millions.
-
Teacher’s pet Eli Lilly announces $850M investment in U.S.
Eli Lilly has publicized plans to invest $850 million in the United States throughout 2017, expanding operations in Indiana and doubling-down on diabetes manufacturing. Just what the president wants to hear.
-
Merck halts late-stage Alzheimer’s trial due to lack of efficacy
Merck announced late Tuesday that it has stopped one of two late-stage Alzheimer’s trials after the external data monitoring committee determined that its BACE1 inhibitor had “virtually no chance of finding a positive clinical effect” in mild-to-moderate AD.
-
Lilly drops $960M to acquire CoLucid and its late-stage migraine drug
Eli Lilly announced Wednesday that it had acquired CoLucid Pharmaceuticals for $960M in an all-cash transaction, regaining ownership of lasmiditan, a late-stage migraine drug that could be commercialized as early as 2018.
-
Late-stage Alzheimer’s failure ripples through the industry
Eli Lilly announced Wednesday that its late-stage trial of solanezumab did not slow progression of Alzheimer’s disease in patients with mild symptoms, triggering a number of biotech shares to fall.
-
Events, Health IT, Pharma, SYN
Pharma’s digital health ambitions: Where are the opportunities and what’s hindering progress?
Looking to the future, Michael Doherty, head of strategic innovation for pharma development at Roche, said: “We are heading to a new model of drug development that will be more flexible, data will be much more continual and contextual…It won’t be dated.”
Promoted
MedCity Spotlight Video: Fruit Street Health on diabetes and telemedicine
Although it has focused on diabetes management, Founder and CEO Laurence Girard says that the company is growing its telemedicine services to include virtual primary care support for other chronic conditions such as hypertension, mental health and smoking cessation that pair community and clinical components.
Promoted
How are healthcare organizations shifting to digital documents?
In order to gain insight into how organizations are thinking about digitizing medical documents and the strategy behind those decisions, we’re conducting a brief survey of the MedCity News audience and will publish a report based on this survey’s findings.
